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OBJECTIVES The purpose of the present study was to compare the use of a mechanical transmyocardial
implant (TMI) device with transmyocardial laser revascularization (TMR) for induction of
therapeutic angiogenesis and arteriogenesis in the chronically ischemic heart.
BACKGROUND Prior experimental studies have demonstrated evidence for neovascularization after both
mechanical and laser transmyocardial revascularization, although a long-term comparison of
the two techniques has not been performed.
METHODS Using an established model of chronic hibernating myocardium, mini-swine underwent 90%
proximal left circumflex (LCx) coronary artery stenosis. One month later, baseline positron
emission tomography (PET) and dobutamine stress echocardiography (DSE) were performed
to quantitate regional myocardial blood flow (MBF) and function. Animals then underwent
TMR with a holmium:yttrium-aluminum-garnet (holmium:YAG) laser (n  5), TMI (n 
5), or sham redo-thoracotomy (n 5). In the TMR group, the entire LCx region was treated
with transmural laser channels at a density of 1/cm2. Transmyocardial implants were placed
transmurally at a similar density in the LCx region of the TMI group. Six months later, the
PET and DSE studies were repeated, and the animals were euthanized.
RESULTS Six months after TMR, there was a significant increase over baseline in resting MBF to the
lased LCx region (68.9 4.6% vs. 89.3 3.0% reference non-ischemic septal segments; p
0.001). This increased MBF was accompanied by a significant improvement in LCx regional
wall motion during peak dobutamine stress (p  0.04). Compared with baseline, there was
no change in LCx region MBF six months after either TMI (72.9  4.8% vs. 85.7  3.4%;
p 0.10) or sham redo-thoracotomy (75.6 4.6% vs. 80.1 5.0%; p 0.2). Likewise, there
was no significant change in rest or stress wall motion by DSE six months postoperatively in
either group. Overall vascular density was increased only in the TMR-treated regions six
months postoperatively. The difference between groups was most notable for a twofold
increase in the number of small arterioles seen in the lased (4.4  0.3 arterioles per high
power field; p  0.001 vs. both TMI and sham) compared with TMI (2.2  0.2) and sham
(1.9  0.2)-treated regions.
CONCLUSIONS Mechanical transmyocardial revascularization with a TMI device does not appear to promote
physiologically significant angiogenesis or arteriogenesis in the chronically ischemic porcine
heart and cannot be recommended for clinical trials at this time. Infrared laser-mediated
injury mechanisms may be important for inducing therapeutic neovascularization with direct
myocardial revascularization techniques. (J Am Coll Cardiol 2002;39:1220–8) © 2002 by
the American College of Cardiology Foundation
Alternative therapies for improving blood flow to the heart
have received increasing attention as the number of patients
with coronary artery disease (CAD) not amenable to more
standard revascularization techniques continues to grow.
These strategies, which include transmyocardial laser revas-
cularization (TMR) (1–5), gene therapy (6–8), and the use
of angiogenic peptides (9,10), have as their goal the pro-
duction of “therapeutic angiogenesis,” or functional new
blood vessel growth in the heart to improve myocardial
oxygen supply. Of these alternative strategies, gene therapy
and angiogenic peptides are still considered experimental
at the present time, although encouraging preclinical
(6,7) and clinical (9,10) data exist to support their use. In
contrast, TMR has been widely used for several years and
is currently approved by the U.S. Food and Drug Ad-
ministration for the treatment of refractory angina pec-
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toris in patients not amenable to bypass surgery or
angioplasty (11).
Numerous studies (12–14) have demonstrated experi-
mental evidence for therapeutic angiogenesis after TMR,
and although the long-term benefits of the procedure are as
yet unproven (15), TMR may prove beneficial in treating
angina pectoris in the thousands of patients with end-stage
CAD. However, there are several disadvantages involved in
the use of TMR, including the need for expensive equip-
ment, the potential for peri-procedural laser malfunction,
the need for regular maintenance and highly specialized
technical support and the risk of laser-induced injury of
patients or medical personnel, among others. Consequently,
if a “non-laser” alternative were available that provided
equivalent clinical benefit, this might be preferred to TMR.
Recent experimental studies using mechanical drilling (16)
and needle punctures (17,18) have suggested that non-laser
mechanical therapies might be capable of promoting angio-
genesis. The purpose of the present study was to examine
long-term (six months) changes in regional myocardial
perfusion using quantitative positron emission tomography
(PET), function with dobutamine stress echocardiography
(DSE), and overall vascular and arteriolar density after
mechanical and laser transmyocardial revascularization in an
established model of chronic hibernating myocardium (19).
The mechanical means of performing transmyocardial re-
vascularization in this study was a novel transmyocardial
implant (TMI) device (20). A prior pilot study, in which six
to eight implants were placed into the lateral wall of the left
ventricle (LV) of non-ischemic swine, demonstrated no
adverse events related to implant placement up to three
months postoperatively. Postmortem histology revealed ev-
idence for blood vessel growth in the region of the implants
(20).
METHODS
Animals. Adult male mini-swine (40 kg) were obtained
from Harlan-Sinclair (Indianapolis, Indiana) and housed
under standard conditions and fed a regular diet. The
Animal Care and Use Committee of Duke University
approved all procedures and protocols. Animals received
humane treatment in compliance with the “Principles of
Laboratory Animal Care” formulated by the National So-
ciety for Medical Research and the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources and published by the Na-
tional Institutes of Health (NIH publication 85-23, revised
1996).
Experimental model. Using a previously described porcine
model of chronic hibernating myocardium (12,13,19), ani-
mals underwent placement of a hydraulic occluder and
ultrasonic flow probe (Transonic Systems, Ithaca, New
York) around the proximal left circumflex (LCx) coronary
artery (Fig. 1). Three days postoperatively, the occluder was
inflated to reduce resting blood flow immediately distal to
the occluder to 10% of baseline. Animals were then kept in
this low-flow state for the duration of the experiment, with
blood flow recordings performed three times weekly to
assure continued occlusion.
Positron emission tomography and DSE. After one
month in the low-flow state, animals underwent PET and
DSE to document the presence of hibernating myocardium
in the LCx distribution. After an overnight fast, dynamic
PET imaging of the heart using 13N-ammonia and 18F-
fluorodeoxyglucose (FDG) was performed as previously
described (12,13,19) to obtain regional estimates of myo-
cardial blood flow (MBF) (ml/g per min) and glucose
utilization (nmol/g per min). The PET scans were inter-
preted as showing hibernating myocardium if reduced
absolute values of MBF were noted in the lateral and
posteroinferior walls of the LV supplied by the LCx,
accompanied by normal or increased FDG uptake in these
same regions (both as compared with the non-ischemic
septum) (21).
The DSE test was performed in 3-min stages with
incremental doses of dobutamine beginning with 5 g/kg/
min and increasing to 40 g/kg per min as previously
described (12,13,19). Based on a standard 16-segment
model (22), wall motion was graded as 1  normal, 2 
hypokinetic, 3  akinetic, or 4  dyskinetic. Regional wall
motion score index (WMSI) was calculated at rest, low dose
and peak stress. Echocardiograms were interpreted in a
blinded manner by a cardiologist with expertise in stress
echocardiography. Using DSE, viability in the LCx region
was defined as an improvement in systolic wall thickening
with low-dose dobutamine in myocardial regions with
severe hypocontractility at rest. Viable segments were con-
sidered ischemic if systolic wall motion deteriorated with
stress (biphasic response) (23).
TMI/sham redo-thoracotomy/TMR. Once hibernating
myocardium in the LCx distribution was demonstrated by
PET and DSE, animals were randomly assigned to either
TMI (n  5), sham redo-thoracotomy (n  5), or TMR
with a holmium:yttrium-aluminum-garnet (holmium:YAG)
laser (Cardiogenesis, Sunnyvale, California) (n  5). All
procedures in all groups were performed within three days
of completion of the baseline PET and DSE studies by a
Abbreviations and Acronyms
CAD  coronary artery disease
DSE  dobutamine stress echocardiography
FDG  fluorodeoxyglucose
holmium:YAG  holmium:yttrium-aluminum-garnet
LCx  left circumflex coronary artery
LV  left ventricle/ventricular
MBF  myocardial blood flow
PET  positron emission tomography
TMI  transmyocardial implant
TMR  transmyocardial laser revascularization
VEGF  vascular endothelial growth factor
WMSI  wall motion score index
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single surgeon using previously described techniques
(12,13). For animals undergoing TMR, 20 channels were
created at 1-cm intervals in the hibernating LCx region.
This number of channels consistently treats the entire LCx
region in this experimental model (12,13). Holmium:YAG
channels were created using multiple 2-J pulses, with a total
energy level of approximately 20 J per channel. Transmural
penetration of laser channels was confirmed by visible
spurting of blood from the channels during systole as well as
a change in the pitch of the sound emitted by the laser as it
passed through the wall and into the blood-filled ventricle.
Laser settings were in accordance with manufacturer rec-
ommendations.
For animals randomized to TMI, an average of 16 (range
14 to 16) transmyocardial implants (Fig. 2) were placed at
approximately 1-cm intervals in the LCx region similar to
TMR. Because of the somewhat larger size of the implants,
slightly fewer numbers, compared with laser channels, were
needed to treat the entire LCx region (Fig. 3). The occluder
and flow probe were left intact. The pericardium was left
widely open. Those animals randomized to the sham group
underwent an identical repent thoracotomy; the pericar-
dium was opened, but TMI/TMR was not performed. In all
cases, continuous LCx occlusion was confirmed postopera-
tively by weekly flow monitoring with the flow probe.
Follow-up PET and DSE. Six months after TMI, sham
redo-thoracotomy, or TMR animals underwent repeat PET
and DSE. This follow-up time point was chosen because it
corresponds to the period of maximal anginal relief seen in
clinical studies of TMR (2). To allow comparisons between
studies performed at baseline and six months and to correct
for the known inter-study variability of absolute values of
MBF by PET (24), normalization of the data was per-
formed using previously described techniques (13,24). For
Figure 1. Coronary angiogram performed immediately prior to euthanasia (six months post-transmyocardial implant) in a representative animal
demonstrating experimental model with location of hydraulic occluder (radiolucent and not seen) and ultrasonic flow probe around proximal left circumflex
(LCx) coronary artery indicated. Note normal left anterior descending (LAD) coronary artery, high-grade stenosis of proximal LCx, and multiple
transmyocardial implants in lateral and posteroinferior walls of the left ventricle.
Figure 2. Transmyocardial implant (TMI) device. The helical TMI is
constructed of stainless steel and has a large anchor coil (on right in figure)
on one end to prevent migration once the device has been implanted in the
myocardium. For implantation, the TMI is mounted on a stainless steel
delivery device (not shown), which has a sharp needle-like tip allowing it
to pierce the epicardium. This places the distal end of the TMI into the
epicardium; the TMI coil is then twisted through the myocardium using
the delivery device such that the TMI spans the entire wall of the heart. An
indicator on the delivery device confirms transmural penetration, after
which the delivery device is removed, leaving the TMI intact.
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each PET study, sectors representing the anterior septum
were used as the normal reference segments (19). The
13N-ammonia activity in sectors representing the LCx
distribution was then expressed as a percentage of the
activity measured in the reference segments.
Analysis of angiogenesis and arteriogenesis. Animals
were euthanized six months after TMI, sham thoracotomy,
or TMR for histologic and histochemical staining to assess
overall vascular and arteriolar density in the LCx region
(12). At the time of euthanasia, the location of the TMIs
was readily apparent owing to their visible anchor coils on
the epicardial surface. Likewise, the TMR channels were
identified as punctate regions of scar tissue easily visible at
the endocardial surface (12). Of the original 16 to 20
mechanical or laser channels per animal, 6 were randomly
chosen for histologic analysis using previously described
techniques (12). Routine histologic staining was performed
with hematoxylin-eosin and Masson trichrome. Angiogen-
esis was assessed using endogenous endothelial alkaline
phosphatase as previously described (12,25,26). Arteriogen-
esis was assessed using immunohistochemical staining for
HHF-35 (Dako, Carpinteria, Califorina), a murine mono-
clonal antibody directed against human smooth muscle
actin. The HHF-35 stains primarily medium and large
arteries (12). Overall vascular density was quantitated in a
blinded fashion by two independent observers using previ-
ously described techniques (26). Endogenous endothelial
alkaline phosphatase staining intensity was measured using
an image analysis system (Olympus IX70 inverted micro-
scope, Optronics DEI-750 image-capturing hardware;
PowerTower Pro 180 CPU). Images were captured using
Adobe Premiere and quantified using NIH image software.
Arteriogenesis was likewise quantitated in a blinded fashion
by two independent observers using a modification of
previously described techniques (12). Four randomly se-
lected samples, each containing at least one channel rem-
nant, were analyzed per animal for a total of 20 samples per
group. Three random high-power (200) fields were ex-
amined per sample. Both vascular and arteriolar density
levels were analyzed for the TMI and TMR channel
remnants and myocardium within 0.5 cm of the channel
remnants. For the sham animals, vascular density was
analyzed on 20 randomly selected samples (4 per animal)
from the ischemic LCx distribution.
Statistical analysis. Results are presented as the mean 
SE. Both MBF and glucose utilization by PET, as well as
WMSI by DSE, were compared within groups using a
paired Student t test with a Bonferroni correction for
multiple comparisons. One-way between-groups analysis of
variance (ANOVA) was used to compare MBF, WMSI,
and vascular density among groups. A p value  0.05 was
considered statistically significant.
Figure 3. Transthoracic echocardiogram in a representative animal after transmyocardial implant (TMI) placement. Note the multiple TMI devices in the
chronically ischemic left circumflex (LCx) distribution (lateral and posteroinferior walls of the left ventricle). Arrows in the upper right indicate the location
of the papillary muscles. The LCx distribution lies between the papillary muscles and has been entirely treated with TMI devices.
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RESULTS
All animals survived to their predetermined euthanasia
dates. There were no major perioperative complications
related to laser or myocardial implant therapy. There was no
migration or breakage of any implant as documented radio-
graphically in the immediate postoperative period, two
weeks postoperatively and again at the time of euthanasia
(Fig. 4). All implants were confined to the wall of the LV at
the time of euthanasia.
Positron emission tomography. Myocardial blood flow by
PET for all groups at baseline and six months’ post
treatment are shown in Table 1. In all animals at baseline,
PET demonstrated a significant decrease in LCx-region
absolute MBF compared with the corresponding non-
ischemic septum and a significant increase in glucose utili-
zation in the regions of decreased blood flow consistent with
myocardial viability and ischemia (data not shown) (21).
There was no difference in normalized baseline LCx-region
MBF among any of the three groups by one-way ANOVA.
No significant change in MBF was seen after either me-
chanical TMI or sham redo-thoracotomy. However, six
months after holmium:YAG TMR, there was a significant
increase in MBF to the lased regions.
Dobutamine stress echocardiography. The DSE data for
the LCx distribution in all groups at baseline and six
months’ post treatment are shown in Table 2. Baseline DSE
in all animals demonstrated severe hypocontractility at rest
Figure 4. Representative postmortem radiograph of an explanted heart demonstrating all 16 transmyocardial implants to be intact and in good posi-
tion.
Table 1. Normalized Left Circumflex Region Myocardial
Perfusion* by PET
Baseline
6 Months
Postoperatively p Value
TMR 68.9  4.6 89.3  3.0  0.001
TMI 72.9  4.8 85.7  3.4 0.10
Sham 75.6  4.6 80.1  5.0  0.2
*Normalized myocardial perfusion (%)  mean perfusion (ml/g per min) LCx region/
mean perfusion (ml/g per min) nonischemic septum.
PET  positron emission tomography; TMI  transmyocardial implant; TMR 
transmyocardial laser revascularization.
Table 2. Regional Wall Motion Score Index (WMSI) for
Hibernating Left Circumflex Distribution by Dobutamine
Stress Echocardiography
Rest Low Stress Peak Stress
TMR baseline 2.1  0.1 1.5  0.2 2.0  0.1
TMR 6 months 2.0  0.2 1.7  0.3 1.6  0.2*
TMI baseline 2.0  0.0 1.3  0.3 1.5  0.1
TMI 6 months 2.1  0.1 1.4  0.2 2.1  0.2
Sham baseline 2.3  0.2 2.0  0.3 2.3  0.2
Sham 6 months 2.3  0.2 1.8  0.4 2.2  0.3
WMSI: 1  normal, 2  hypokinetic, 3  akinetic, 4  dyskinetic. *p  0.04 for
peak stress regional WMSI six months’ post-TMR vs. baseline.
TMI  transmyocardial implant; TMR  transmyocardial laser revascularization.
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in the LCx region. As shown in Table 2, wall motion in
these regions demonstrated a biphasic response of initial
improvement (reduced WMSI) during low-dose dobut-
amine infusion followed by deterioration with high-dose
dobutamine stimulation consistent with ischemic, viable
myocardium in the LCx distribution (23). There was no
difference in baseline rest or stress LCx-region WMSI
between any of the three groups by one-way ANOVA.
There was no significant change in rest WMSI six months
postoperatively in any group. Likewise, there was no signif-
icant improvement in peak stress regional WMSI six
months after sham redo-thoracotomy or mechanical TMI.
In fact, there was a trend toward increased inducible
ischemia at peak dobutamine stress in the TMI group (p 
0.06). On the contrary, there was a significant improvement
(p 0.04) in regional WMSI for the lased segments at peak
stress, consistent with a reduction in ischemia, six months
after holmium:YAG laser TMR.
Vascular and arteriolar density. The TMI and TMR
channel remnants were easily identified on histologic stain-
ing as hypocellular regions filled with connective tissue.
Similar-appearing regions (Fig. 5) were observed six months
after TMR and TMI. In no instance were patent channels
seen after either treatment. Histologic analysis of the
ischemic LCx region in animals undergoing sham redo-
thoracotomy was unremarkable, with no areas of increased
connective tissue. Endogenous endothelial alkaline phos-
phatase staining demonstrated numerous blood vessels ad-
jacent to and within the holmium:YAG laser channel
remnants (Fig. 6). Significantly fewer numbers of vessels
were seen in and around the TMI channels and in non-lased
(sham) LCx myocardium. Quantitative vascular density
analysis confirmed these observations (Fig. 7A) with a
threefold increase in vascular density in TMR-treated myo-
cardium compared with either TMI or sham redo-
thoracotomy. This increased vascularity in the lased regions
was in large part due to a twofold increase in the number of
arterioles (Fig. 7B), as demonstrated by HHF-35 immuno-
histochemical staining (Fig. 8), in the lased areas (4.4  0.3
arterioles/HPF; p  0.001 vs. both TMI [2.2  0.2] and
sham [1.9  0.2]-treated regions) consistent with arterio-
genesis. Interobserver variability for vascular density mea-
surements was 10%.
DISCUSSION
TMR-induced angiogenesis and arteriogenesis. To date,
six prospective randomized controlled trials have demon-
strated the efficacy of surgical TMR for decreasing anginal
symptoms in patients ineligible for traditional methods of
revascularization (1–5,27). One of the proposed mecha-
nisms of action of TMR is improved regional perfusion via
angiogenesis (11). This angiogenesis hypothesis holds that
laser-induced injury and the subsequent inflammatory re-
sponse leads to new blood vessel growth with a secondary
improvement in anginal symptoms due to an increase in
local oxygen delivery. A number of animal studies in various
ischemic models lend support to this hypothesis (12–
Figure 5. Masson trichrome staining (100) showing (A) hypocellular transmyocardial implant channel remnant filled with blue-staining connective tissue.
Large region devoid of connective tissue within channel remnant is prior location of coil of implant device, which has been removed post mortem.
Similar-appearing region six months post-transmyocardial laser revascularization is shown in (B).
Figure 6. Endogenous endothelial alkaline phosphatase staining (original magnification 100) of representative sections from hibernating myocardium
treated with sham redo-thoracotomy (A), transmyocardial implant (TMI) (B), and holmium yttrium:aluminum:garnet transmyocardial laser revascular-
ization (TMR) (C). Note the significantly greater blue-staining intensity, characteristic of endothelial cells, in (C) compared with (B) and (A). The number
of blue-staining blood vessels is greater both within and adjacent to the TMR channel remnant (C) compared with that seen with TMI (B).
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14,28,29). However, several studies have suggested that the
angiogenic response to TMR is a non-specific response to
injury, which may be produced using mechanical means.
Malekan et al. (16) found no significant difference in
vascular density in normal ovine myocardium four weeks
after treatment with CO2 laser or mechanical drill, both of
which significantly increased vascular density over untreated
control regions. Likewise, in chronically ischemic porcine
hearts, Chu et al. (17) found a similar increase in vascular
endothelial growth factor (VEGF) protein levels as well as
vascular density one week after TMR using either a CO2
laser or 18-gauge hypodermic needle. A follow-up study
from this same laboratory found an increase in angiogenic
growth factor expression and neovascularization up to four
weeks after transmyocardial revascularization using an 18-
gauge needle (18).
The most distal experimental end point for assessing
therapeutic angiogenesis and arteriogenesis is assessment of
regional function and perfusion, because these represent the
ultimate desired effect of angiogenic interventions (25).
However, no study to date has compared functional data,
including measurements of regional perfusion and function,
after laser and mechanical revascularization. In addition,
there are no long-term studies (4 weeks) comparing
mechanical and laser therapies. Consequently, the pur-
pose of the present study was to compare the long-term
angiogenic and arteriogenic response in the chronically
ischemic heart after treatment with a novel TMI device or
holmium:YAG TMR. The device used (Fig. 2) has previ-
ously been demonstrated safe in a pilot study in non-
ischemic swine (20). The present study demonstrates that
the mechanical TMI device employed does not significantly
improve regional MBF, function or vascular density six
months after treatment in hibernating porcine myocardium.
On the contrary, consistent with prior experimental work
(12–14,28), there was a significant increase in MBF by PET
and contractile reserve by DSE six months after holmium:
YAG TMR. These functional improvements were accom-
panied by significant neovascularization in the lased regions.
No changes in MBF, function, or vascular density were seen
in control animals undergoing sham redo-thoracotomy.
Mechanical versus laser tissue effects. Angiogenesis refers
to the sprouting of new capillaries from pre-existing ones
and is mainly caused by hypoxia and mediated via activation
of hypoxia-inducible factor (HIF-1), which serves to
increase transcription of VEGF and its receptors and
stabilize VEGF mRNA (30). Arteriogenesis, on the other
hand, is the growth of arteries from pre-existing arterioles,
and it is the only relevant type of vascular growth capable of
carrying significant blood flow (31). Primary arteriogenic
stimuli include shear stress and inflammation where an
Figure 7. Quantitative (A) vascular and (B) arteriolar density analysis. See
text for details. TMI  transmyocardial implant; TMR  transmyocardial
laser revascularization.
Figure 8. Anti-smooth muscle actin (HHF-35) staining (original magnification 40) of representative sections from hibernating myocardium treated with
sham redo-thoracotomy (A), transmyocardial implant (B), and holmium:yttrium-aluminum-garnet transmyocardial laser revascularization (C). Note
numerous red-staining arterioles in (C) compared with (B) and (A).
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invasion of monocytes and other white blood cells leads to
the production of growth factors such as the fibroblast
growth factors with subsequent vascular growth (30–32).
Mechanical means of performing transmyocardial revascu-
larization produce tissue effects generally confined to their
path through the myocardium. Lasers on the other hand,
produce a zone of reversible injury distant from the laser
channels (33), the degree of which varies with the type of
laser used (34). Consequently, one might hypothesize that
the use of laser energy, with its increased inflammatory
response, might yield greater arteriogenesis compared with
mechanical means. This is supported by the finding in the
present study of a twofold increase in the number of
arterioles in the lased regions compared with those treated
with the mechanical implant device or sham thoracotomy.
Because nearly equal numbers of TMI and TMR channels
were placed within the ischemic regions, the “efficiency” of
TMR, described as the amount of arteriogenesis for a given
number of channels (18), appears to be superior to that of
mechanical transmyocardial revascularization.
Two recent studies support this hypothesis. The first was
a comparison of holmium:YAG, CO2, and xenon chloride
excimer lasers performed in our laboratory (26). Both
holmium:YAG and CO2 are infrared lasers that use thermal
ablation to create transmyocardial channels. Excimer lasers,
in contrast, are “cold” lasers that operate deep within the
ultraviolet spectrum and produce tissue ablation via disso-
ciation of molecular bonds (26). Consequently, excimer
lasers are more purely ablative and produce less damage of
surrounding myocardium than the infrared lasers, similar to
mechanical means of transmyocardial revascularization.
Consistent with the results of the present work, that
study (35) demonstrated that the holmium:YAG and CO2
lasers produced a greater neovascularization response in
ischemic porcine myocardium than excimer laser TMR.
Additionally, Hamawy and colleagues (36) have demon-
strated a dose response to the number of channels produced
with an excimer laser. Their study (36), which found no
increase in perfusion four weeks after treatment of a given
area of ischemic porcine myocardium with 10 or 25 excimer-
lased channels but a significant increase when the same area
was treated with 50 channels, also supports the theory that
the efficiency of infrared laser TMR is greater than that of
mechanical means, as a greater number of channels were
needed to produce a given level of neovascularization.
Finally, one might hypothesize that, because infrared laser
TMR appears to require fewer channels than mechanical
means to produce a given degree of angiogenesis, the larger
number of mechanical punctures might ultimately result in
greater scarring and less functional improvement.
Study limitations. Limitations of the present study are
several. First, the number of animals per group is somewhat
small, and consequently the possibility of a type II error
exists. Specifically, the trend toward improved regional
myocardial perfusion in the mechanical TMI group poten-
tially might have reached significance had the pattern held
up in a larger number of animals. However, the complete
absence of improvement in regional function in the TMI
group (unlike TMR) would suggest that the lack of statis-
tical significance in MBF is accurate.
Another limitation is that the presence of the LV metal
implants in the TMI group made blinding of their
follow-up echocardiograms impossible, thus allowing for
the potential introduction of observer bias. Finally, the
physiologically significant angiogenesis and arteriogenesis
seen after laser TMR in the present study, although in
agreement with prior experimental work (12–14,28,36),
does contrast with the results of human trials that have not
consistently demonstrated improvements in regional perfu-
sion or function after TMR (1,3,4). The reasons for this
discrepancy are not entirely clear but may relate to differ-
ences between the animal model utilized and human sub-
jects. Unlike the human subjects with severe multi-vessel
disease enrolled in the clinical trials, the experimental model
used in this and most other preclinical studies of pro-
angiogenic therapies is one of single-vessel disease where
the remaining vessels are normal and thus potentially more
able to form collateral vessels capable of improving MBF to
the ischemic regions.
Conclusions. This study demonstrates that the mechanical
TMI device tested does not significantly improve regional
MBF, function, or vascular density six months after treat-
ment in hibernating porcine myocardium. On the contrary,
TMR with a holmium:YAG laser did increase regional
myocardial perfusion and improve function while being
accompanied by a significant arteriogenic response as dem-
onstrated on immunohistochemical staining. Because both
therapies were administered in relatively equivalent “doses,”
the results suggest that infrared laser may be more efficient
than mechanical therapies for the induction of therapeutic
angiogenesis and arteriogenesis in the ischemic heart.
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